Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 7484-7491

  Chen, Z H ^a   Wang, L ^a   Luo, L P ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

ERCC1; Gastric cancer; Oxaliplatin 5 Fu survival; Response; XPF

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; XERODERMA PIGMENTOSUM GROUP F PROTEIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DNA REPAIR; DRUG EFFICACY; DRUG RESPONSE; ERCC1 GENE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; STOMACH CANCER; SURVIVAL TIME; XPF GENE; AGED; ALLELE; CANCER STAGING; GENETIC POLYMORPHISM; GENETICS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RISK FACTOR; STOMACH NEOPLASMS; TREATMENT OUTCOME;

AGED; ALLELES; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84907148376     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.September.12.15     Document Type: Article

References (27)

1. Alexander BM, Sprott K, Farrow DA, Wang X, et al. (2010). DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin. Cancer Res. 16: 5796-5804.
2. Alexander BM, Wang XZ, Niemierko A, Weaver DT, et al. (2012). DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 83: 164-171.
3. Carles J, Monzo M, Amat M, Jansa S, et al. (2006). Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 66: 1022-1030.
4. De Silva IU, McHugh PJ, Clingen PH and Hartley JA (2000). Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell Biol. 20: 7980-7990.
5. DeLoia JA, Bhagwat NR, Darcy KM, Strange M, et al. (2012). Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol. Oncol. 126: 448-454.
6. Fareed KR, Al-Attar A, Soomro IN, Kaye PV, et al. (2010). Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br. J. Cancer 102: 1600-1607.
7. Fleming ND, Agadjanian H, Nassanian H, Miller CW, et al. (2012). Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer 118: 689-697.
8. Friedberg EC (2001). How nucleotide excision repair protects against cancer. Nat. Rev. Cancer 1: 22-33.
9. Goode EL, Ulrich CM and Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11: 1513-1530.
10. Gustavsson B, Kaiser C, Carlsson G, Wettergren Y, et al. (2009). Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int. J. Cancer 124: 1220-1226.
11. International Agency for Research on Cancer (IARC) (2008). Globocan 2008: Stomach Cancer Incidence, Mortality and Prevalence Worldwide in 2008.
12. Kornguth DG, Garden AS, Zheng Y, Dahlstrom KR, et al. (2005). Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. Int. J. Radiat. Oncol. Biol. Phys. 62: 665-671.
13. Liang J, Li QF, Yao RY, Lu HY, et al. (2010). Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy. Zhonghua Zhong Liu Za Zhi 32: 515-519.
14. MacDonald JS (2004). Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother. Pharmacol. 54 (Suppl 1): S4-11.
15. Matsubara J, Nishina T, Yamada Y, Moriwaki T, et al. (2008). Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br. J. Cancer 98: 832-839.
16. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981). Reporting results of cancer treatment. Cancer 47: 207-214.
17. Ozkan M, Akbudak IH, Deniz K, Dikilitas M, et al. (2010). Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac. J. Cancer Prev. 11: 181-185.
18. Reed E (1998). Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 24: 331-344.
19. Vaezi A, Wang X, Buch S, Gooding W, et al. (2011). XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 17: 5513-5522.
20. Wang AT, Sengerova B, Cattell E, Inagawa T, et al. (2011). Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev. 25: 1859-1870.
21. Wang L, Wei J, Qian X, Yin H, et al. (2008). ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 8: 97.
22. Wang Z, Chen JQ, Liu JL, Qin XG, et al. (2012). Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol. 12: 137.
23. Wohrer SS, Raderer M and Hejna M (2004). Palliative chemotherapy for advanced gastric cancer. Ann. Oncol. 15: 1585- 1595.
24. Wood RD, Mitchell M, Sgouros J and Lindahl T (2001). Human DNA repair genes. Science 291: 1284-1289.
25. Yin M, Yan J, Martinez-Balibrea E, Graziano F, et al. (2011). ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin. Cancer Res. 17: 1632-1640.
26. Yun J, Kim KM, Kim ST, Kim JH, et al. (2010). Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res. Treat. 42: 101-106.
27. Zhu XD, Niedernhofer L, Kuster B, Mann M, et al. (2003). ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol. Cell 12: 1489-1498.